March 2019 Issue - Endovascular Today

Table of Contents

Issue

March 2019

EVAR

What Does the Future Hold?

Supplement

Thrombolysis for Peripheral Arterial Thrombosis

Leading French experts discuss the place of thrombolysis in the modern era.

In This Issue

Guest Chief Medical Editors' Page

EVAR—What Does the Future Hold?

By Ali Azizzadeh, MD, FACS; and Dittmar Böckler, MD, PhD

Cover Stories

Proper and Timely Detection of Seal Failure After EVAR

Using detailed imaging analysis and dedicated software to identify subtle changes in endograft geometry within the aortic neck prior to late failure.

By Richte C.L. Schuurmann, PhD; Cornelis G. Vos, MD, PhD; and Jean-Paul P.M. de Vries, MD, PhD

Does Finite Element Analysis Enable Us to Predict Rupture?

The benefits and limitations of finite element analysis in patients with abdominal aortic aneurysms.

By Philipp Erhart, MD; Moritz Lindquist Liljeqvist, MD; Joy Roy, MD, PhD; T. Christian Gasser, PhD; and Dittmar Böckler, MD, PhD

AAA Screening: How Can the Challenge Be Effectively and Efficiently Met?

The President of the German Society of Vascular Surgery and Vascular Medicine discusses Germany's nationwide AAA screening program, the challenges and potential drawbacks to screening, and the use of monitoring devices in aortic health.

With Dittmar Böckler, MD, PhD

Genetics and Hereditary Factors of Aortic Disease: Applying What We Know, Exploring What We Don't

A discussion on the current landscape of genetics research related to diagnosing and treating aortic disease.

With Dianna M. Milewicz, MD, PhD

Anticipating the 2019 AAA NICE Guidelines

Prof. Loftus shares his thoughts on the impending publication of the UK's NICE updated guidelines for abdominal aortic aneurysm treatment and the potential effects they may have on practice and patients.

With Ian M. Loftus, MD, FRCS

EVAR in 3D: The Seattle Experience

Insight into the creation and use of Aortica Corporation's AortaFit software application to generate 3D-printed, patient-specific, fenestrated endograft templates for treating juxtarenal abdominal aortic aneurysms.

With Benjamin W. Starnes, MD, FACS

EVAR in 3D: The Leipzig Experience

Exploring the role of three-dimensional printing in preprocedural planning and custom fenestration in physician-modified grafts to treat acute, complex abdominal and thoracoabdominal aortic pathologies.

By Daniela Branzan, MD; Andrej Schmidt, MD, PhD; Dirk Winkler, MD, PhD; Dierk Scheinert, MD, PhD; and Ronny Grunert, PhD

Ask the Experts: The Biggest Breakthrough in AAA Therapy in the Next Decade Will Involve…

Experts contemplate necessary advancements in the next era of AAA management, including new imaging technology, an understanding of the role of genetics and genomics, and EVAR improvements.

With Juan Parodi, MD; Edward Y. Woo, MD; Shirling Tsai, MD; and Takao Ohki, MD

Superficial Venous Disease Update

Ask the Experts: Which Factors Have the Most Influence on Your Decision-Making Regarding the Treatment of Perforators?

Leading venous practitioners share their treatment algorithms for when it is appropriate to intervene on perforator veins and when it is not.

With Melvin Rosenblatt, MD; Sergio Gianesini, MD, PhD, FACS; Ellen D. Dillavou, MD, FACS; Thomas Proebstle, MD; and Kathleen Gibson, MD, FACS

Ask the Experts: If a Government Health Oversight Agency Offered You Full Funding for a Superficial Venous Trial, What Would You Study and Why?

Leading venous practitioners outline the trials that they believe are most urgently needed.

With Sarah Onida, BSc, MBBS, MRCS, PhD; Elna Masuda, MD; and Johann Chris Ragg, MD

What's in a Society Name? From ACP to AVLS

The Immediate Past President of the American College of Phlebology discusses the recent change in the society's name, as well as its continued efforts and evolving goals.

With Neil Khilnani, MD, FSIR, FACPh

Continuing Coverage: Paclitaxel In Pad

On the Paclitaxel Meta-Analysis: A Conversation With Konstantinos Katsanos, MD

Dr. Katsanos discusses the methods and findings of his group's meta-analysis, the patient-level data presented in response, and potential next steps.

Highlights From the VIVA Vascular Leaders Forum on Paclitaxel Safety

Points of consensus, contention, and paths forward.

Featured Technology